With crashes occupying most of the talk at the Tour De France, the race now in its 98th year has been hit by the news that Katusha's Alexandr Kolobnev has failed a test for banned substance Hydrochlorothiazide.
The Russian provided a urine sample on July 6th and the Châtenay-Malabry laboratory noted an adverse analytical finding for Hydrochlorothiazide, according to a statement issued by cycling union - UCI tonight.
The full UCI statement reads:
Earlier today, the UCI advised the Russian rider Alexandr Kolobnev of an Adverse Analytical Finding (presence of Hydrochlorothiazide based on the report from the WADA accredited laboratory in Châtenay-Malabry) in the urine sample collected from him at an in competition test at the Tour de France on 6 July 2011. Mr. Kolobnev has the right to request and attend the analysis of his B sample.
The UCI Anti-Doping Rules do not provide for a provisional suspension given the nature of the substance, which is a specified substance.
However the UCI is confident that his team will take the necessary steps to enable the Tour de France to continue in serenity and to ensure that their rider has the opportunity to properly prepare his defense in particular within the legal timeline, which allows four days for him to have his B sample analyzed.
Under the World Anti-Doping Code and the UCI Anti-Doping Rules, the UCI is unable to provide any additional information at this time.